Millipore reports redemption completion of outstanding 3.75% Convertible Senior Notes Due 2026

Millipore Corporation, the Life Science business of Merck KGaA of Germany, that operates as EMD Millipore in the U.S. and Canada, today announced that all its remaining outstanding 3.75% Convertible Senior Notes Due 2026 (the "Notes") were redeemed on December 1, 2011, at one hundred percent (100%) of the outstanding principle amount of the Notes.

Most of the Notes were already converted by its holders between June and August 2010 in connection with certain conversion rights resulting from the acquisition of Millipore Corporation by Merck KGaA, and only a principal amount of US$ 27.2 million of the originally issued notes in the principal amount of US$ 550 million remained outstanding upon the call for redemption as of December 1, 2011. All remaining outstanding Notes have now been redeemed.

Millipore had announced the intended redemption on November 1, 2011, and notified holders of the Notes accordingly. As a result of the call for redemption, the Notes could also be surrendered by their holders for conversion, and independent of such redemption and related conversion right, holders of the Notes also had the right, at their option, to require Millipore to purchase their Notes on December 1, 2011, at a purchase price, payable in cash, equal to one hundred percent (100%) of the principal amount of the Notes, or to surrender their Notes for conversion at any time between November 1, 2011, and December 1, 2011.

All notes of holders that did not exercise any of these rights were automatically redeemed on December 1, 2011, and no Notes remain outstanding.

Source Millipore Corporation